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Statement of findings
We assessed the association between a glutamine repeat polymorphism in AIB1 and breast
cancer risk in a case–control study (464 cases, 624 controls) nested within the Nurses’
Health Study cohort. We observed no association between AIB1 genotype and breast
cancer incidence, or specific tumor characteristics. These findings suggest that AIB1 repeat
genotype does not influence postmenopausal breast cancer risk among Caucasian women
in the general population.
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terone receptor; SD = standard deviation; SRC = steroid receptor coactivator.
Introduction: A causal association between endogenous and
exogenous estrogens and breast cancer has been established.
Steroid hormones regulate the expression of proteins that are
involved in breast cell proliferation and development after
binding to their respective steroid hormone receptors.
Coactivator and corepressor proteins have recently been
identified that interact with steroid hormone receptors and
modulate transcriptional activation [1]. AIB1 (amplified in
breast 1) is a member of the steroid receptor coactivator
(SRC) family that interacts with estrogen receptor (ER)a in a
ligand-dependent manner, and increases estrogen-dependent
transcription [2]. Amplification and overexpression of AIB1 has
been observed in breast and ovarian cancer cell lines and in
breast tumors [2,3]. A polymorphic stretch of glutamine amino
acids, with unknown biologic function, has recently been
described in the carboxyl-terminal region of AIB1 [4]. Among
women with germline BRCA1 mutations, significant positive
associations were observed between AIB1 alleles with 26 or
fewer glutamine repeats and breast cancer risk [5]
Aim: To establish whether AIB1 repeat alleles are associated
with breast cancer risk and specific tumor characteristics
among Caucasian women.
Patients and methods: We evaluated associations
prospectively between AIB1 alleles and breast cancer risk in
the Nurses’ Health Study using a nested case–control design.
The Nurses’ Health Study was initiated in 1976, when 121700
US-registered nurses between the ages of 30 and 55 years
returned an initial questionnaire reporting medical histories and
baseline health-related exposures. Between 1989 and 1990
blood samples were collected from 32826 women. Eligible
cases in this study consisted of women with pathologically
confirmed incident breast cancer from the subcohort who gave
a blood specimen. Cases with a diagnosis anytime after blood
collection up to June 1, 1994, with no previously diagnosed
cancer except for nonmelanoma skin cancer were included.
Controls were randomly selected participants who gave a
blood sample and were free of diagnosed cancer (except
nonmelanoma skin cancer) up to and including the interval in
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which the cases were diagnosed, and were matched to cases
on year of birth, menopausal status, postmenopausal hormone
use, and time of day, month and fasting status at blood
sampling. The nested case–control study consisted of 464
incident breast cancer cases and 624 matched controls. The
protocol was approved by the Committee on Human Subjects,
Brigham and Womens’ Hospital, Boston, Massachusetts USA.
Information regarding breast cancer risk factors was obtained
from the 1976 baseline questionnaire, subsequent biennial
questionnaires, and a questionnaire that was completed at the
time of blood sampling. Histopathologic characteristics, such
as stage, tumor size and ER and progesterone receptor (PR)
status, were ascertained from medical records when available
and used in case subgroup analyses.
AIB1 repeat alleles were determined by automated fluorescence-
based fragment detection from polymerase chain reaction
(PCR)-amplified DNA extracted from peripheral blood
lymphocytes. Fluorescent 5¢-labeled primers were utilized for
PCR amplification, and glutamine repeat number discrimination
was performed using the ABI Prism 377 DNA Sequencer
(Perkin-Elmer, Foster City, CA, USA). Genotyping was
performed by laboratory personnel who were blinded to
case–control status, and blinded quality control samples were
inserted to validate genotyping identification procedures
(n = 110); concordance for the blinded samples was 100%.
Methods regarding plasma hormone assays have previously
been reported [6]. Conditional and unconditional logistic
regression models, including terms for the matching variables
and other potential confounders, were used to assess the
association of AIB1 alleles and breast cancer characterized by
histologic subtype, stage of disease, and ER and PR status.
We also evaluated whether breast cancer risk associated with
AIB1 genotype differed within strata of established breast
cancer risk factors, and whether repeat length in AIB1
indirectly influenced plasma hormone levels.
Results: The case–control comparisons of established breast
cancer risk factors among these women have previously been
reported [7], and are generally consistent with expectation. The
mean age of the women was 58.3 (standard deviation [SD]
7.1) years, ranging from 43 to 69 years at blood sampling.
There were 188 premenopausal and 810 postmenopausal
women, with mean ages of 48.1 (SD 2.8) years and 61.4 (SD
5.0) years, respectively, at blood sampling. Women in this
study were primarily white; Asians, African-Americans and
Hispanics comprised less than 1% of cases or controls.
The distribution of AIB1 glutamine repeat alleles and AIB1
genotypes for cases and controls are presented in Table 1.
Women with AIB1 alleles of 26 glutamine repeats or fewer
were not at increased risk for breast cancer (odds ratio [OR]
1.01, 95% confidence interval [CI] 0.75–1.36; Table 2).
Results were also similar by menopausal status and in analyses
additionally adjusting for established breast cancer risk factors.
Among premenopausal women, the OR for women with at least
one allele with 26 glutamine repeats or fewer was 0.82 (95%
CI 0.37–1.81), and among postmenopausal women the OR
was 1.09 (95% CI 0.78–1.52; Table 2). We did not observe
evidence of a positive association between shorter repeat
length and advanced breast cancer, defined as women with
breast cancer having one or more involved nodes (OR 1.07,
95% CI 0.64–1.78), or with cancers with a hormone-
dependent phenotype (ER-positive: OR 1.16, 95% CI
0.81–1.65; Table 3). No associations were observed among
women who had one or more alleles with 26 glutamine repeats
or fewer, with or without a family history of breast cancer (family
history: OR 1.09; 95% CI 0.46–2.58; no family history: OR
0.94; 95% CI 0.68–1.31; test for interaction P = 0.65). We
also did not observe associations with breast cancer risk to be
modified by other established breast cancer risk factors.
Among postmenopausal controls not using postmenopausal
hormones, geometric least-squared mean plasma levels of
estrone sulfate and estrone were similar among carriers and
noncarriers of AIB1 alleles with 26 glutamine repeats or fewer
(both differences: £ +3.5%; P > 0.50). Mean levels of estradiol
were slightly, but nonsignificantly elevated among carriers of
alleles with 26 glutamine repeats or fewer (+11.6%; P = 0.08).
Table 1
AIB1 allele* and genotype frequency among cases and
controls, Nurses’ Health Study 1989–1994
AIB1 allele Cases (n [%]) Controls (n [%])
19 0 (0.0) 1 (0.1)
22 0 (0.0) 1 (0.1)
25 1 (0.1) 1 (0.1)
26 111 (12.0) 148 (11.9)
27 3 (0.3) 3 (0.2)
28 375 (40.4) 485 (38.9)
29 431 (46.4) 597 (47.8)
30 4 (0.4) 10 (0.8)
31 2 (0.2) 2 (0.2)
34 1 (0.1) 0 (0.0)
Total 928 1248
AIB1 genotype Cases (n [%]) Controls (n [%])
19/29 0 (0) 1 (0.2)
22/29 0 (0) 1 (0.2)
25/28 0 (0) 1 (0.2)
25/29 1 (0.2) 0 (0.0)
26/26 9 (1.9) 10 (1.6)
26/28 45 (9.7) 55 (8.8)
26/29 47 (10.1) 71 (11.4)
26/30 1 (0.2) 2 (0.3)
27/28 2 (0.4) 1 (0.2)
27/29 1 (0.2) 2 (0.3)
28/28 64 (13.8) 98 (15.7)
28/29 196 (42.2) 228 (36.5)
28/30 2 (0.4) 3 (0.5)
28/31 1 (0.2) 1 (0.2)
28/34 1 (0.2) 0 (0.0)
29/29 92 (19.8) 144 (23.1)
29/30 1 (0.2) 5 (0.8)
29/31 1 (0.2) 1 (0.2)
Total 464 624
*There was no significant difference in frequency of alleles with 26
repeats or fewer between cases and controls (P = 0.82).Breast Cancer Research    Vol 2 No 5 Haiman et al
Introduction
A causal association between endogenous and exoge-
nous estrogens and breast cancer development has been
established [6,8,9]. Variant alleles of candidate genes
involved in steroid hormone production (eg CYP17,
CYP19 and 17b-HSD) [7,10–13] and polymorphic vari-
ants in steroid hormone receptors (eg ERa, PR and AR)
[14–17] are currently being evaluated as potential high
prevalence, low penetrance markers of breast cancer risk.
Women with biologically functional polymorphisms in
these genes may be exposed to increased levels of circu-
lating steroid hormones or enhanced activity of hormone-
responsive genes, and thus have altered susceptibility to
steroid hormone-associated cancers.
Steroid hormones regulate the expression of proteins that
are involved in breast cell proliferation and development
after binding to their respective steroid hormone receptors.
Discussion: In this population-based nested case–control
study, women with at most 26 repeating glutamine codons
(CAG/CAA) within the carboxyl terminus of AIB1 were not at
increased risk for breast cancer. We did not observe shorter
repeat alleles to be positively associated with breast cancer
grouped by histologic subtype, stage of disease, or by ER and
PR status. These data suggest that AIB1 repeat length is not a
strong independent risk factor for postmenopausal breast
cancer, and does not modify the clinical presentation of the
tumor among Caucasian women in the general population.
Table 2
Association of AIB1 genotype and breast cancer risk, Nurses’
Health Study 1989–1994
Premenopausal Cases Controls OR* 95% CI
No of alleles with 26 or fewer repeats
0 49 51 1.00
1 14 16 0.91 0.40–2.09
2 1 3 0.32 0.03–3.25
1 or 2 15 19 0.82 0.37–1.81
Postmenopausal Cases Controls OR† 95% CI
No of alleles with 26 or fewer repeats
0 275 397 1.00
1 75 106 1.04 0.74–1.46
2 8 7 1.90 0.67–5.42
1 or 2 83 113 1.09 0.78–1.52
Combined analysis Cases Controls‡ OR§ 95% CI
No of alleles with 26 or fewer repeats
0 361 476 1.00
1 94 129 0.99 0.73–1.35
2 9 10 1.29 0.52–3.23
1 or 2 103 139 1.01 0.75–1.36
AIB1 genotype¶
29/29 92 141 1.00
28/29 196 227 1.27 0.91–1.77
28/28 64 95 0.99 0.65–1.50
26/29 47 69 1.04 0.66–1.64
26/28 45 55 1.23 0.75–2.02
26/26 9 10 1.48 0.57–3.81
*Unconditional logistic regression adjusted for the matching variables:
age, date of blood sampling, time of blood sampling and fasting status.
†Unconditional logistic regression adjusted for the matching variables:
age, postmenopausal hormone use, date of blood sampling, time of
blood sampling and fasting status. ‡Nine controls were excluded due
to incomplete matching. §Conditional logistic regression adjusted for
the matching variables: age, menopausal status, postmenopausal
hormone use, date of blood sampling, time of blood sampling and
fasting status. ¶Genotypes combined and modeled together, but not
included in table (cases, controls): 19/29 (0, 1), 22/29 (0, 1), 25/28
(0, 1), 25/29 (1, 0), 26/30 (1, 2), 27/28 (2, 1), 27/29 (1, 2), 28/30 (2,
3), 28/31 (1, 1), 28/34 (1, 0), 29/30 (1, 5), and 29/31 (1, 1).
Table 3
Associations between AIB1 genotypes and breast cancer risk
by histologic subtype and receptor status
No of AIB1 alleles
with £26 repeats
Controls/cases 0 1 or 2 OR* 95% CI
Controls 483 141
Cases†
Invasive 295 93 1.13 0.83–1.54
Ductal 252 79 1.10 0.81–1.53
Lobular 33 9 1.05 0.48–2.30
Involved nodes
³1 83 24 1.07 0.64–1.78
³4 30 6 0.72 0.29–1.81
Receptor status
ER+ 189 61 1.16 0.81–1.65
ER– 46 12 0.94 0.47–1.85
PR+ 142 45 1.14 0.77–1.69
PR– 86 24 1.03 0.63–1.71
Tumor size
£2 cm 207 64 1.13 0.80–1.60
>2 cm 74 25 1.21 0.73–2.00
Degree of differentiation
High or  98 37 1.36 0.89–2.10
moderate
Poor 55 23 1.54 0.90–2.64
*Unconditional logistic regression adjusted for matching variables: age,
menopausal status, postmenopausal hormone use, date of blood
sampling, time of blood sampling and fasting status. †Numbers do not
add up to total for invasive cancer because of missing data.
Full articleCoactivator and corepressor proteins have recently been
identified that interact with steroid hormone receptors and
modulate transcriptional activation [1]. AIB1 is a member
of the SRC family that interacts with ERa in a ligand-
dependent manner and increases estrogen-dependent
transcription [2]. Amplification and over-expression of
AIB1 has been observed in breast and ovarian cancer cell
lines and in breast tumors [2,3]. A polymorphic stretch of
glutamine amino acids, with unknown biologic function,
has recently been described in the carboxyl-terminal
region of AIB1 [4]. The androgen receptor has a similar
polymorphic glutamine region, and shorter repeat lengths
have been associated with increased risk of prostate
cancer [18]. Among women with germline BRCA1 muta-
tions, significant positive associations were observed
between  AIB1 alleles of 26 or fewer glutamine repeats
and breast cancer risk [5].
The goal of the present study was to establish whether
AIB1 repeat alleles are associated with breast cancer risk
among Caucasian women. We evaluated associations
prospectively between AIB1 alleles and breast cancer risk
in the Nurses’ Health Study using a nested case–control
design. We investigated potential interactions between
AIB1 alleles and established breast cancer risk factors,
and whether specific repeat alleles may provide a growth
advantage for the developing malignancy and thus be
associated with histopathologic tumor characteristics. We
also examined whether repeat length in AIB1 indirectly
influences plasma hormone levels.
Patients and methods
Study population
The Nurses’ Health Study was initiated in 1976, when
121700 US-registered nurses between the ages of 30
and 55 years returned an initial questionnaire reporting
medical histories and baseline health-related exposures.
Updated information has been obtained by questionnaire
every 2 years, including data on reproductive variables,
and oral contraceptive and postmenopausal hormone use.
Incident breast cancers are identified by self-report and
confirmed by medical record review. Between 1989 and
1990, blood samples were collected from 32826 women.
Approximately 97% of the blood samples were returned
within 26 h of being drawn, immediately centrifuged,
aliquoted into plasma, red blood cells and buffy coat frac-
tions, and stored in liquid nitrogen freezers. Subsequent
follow up has been greater than 98% for this subcohort.
Eligible cases in this study consisted of women with
pathologically confirmed incident breast cancer from the
subcohort who gave a blood specimen. Cases with a
diagnosis anytime after blood collection up to June 1,
1994, with no previously diagnosed cancer except for
nonmelanoma skin cancer were included. Controls were
randomly selected participants who gave a blood sample
and were free of diagnosed cancer (except nonmelanoma
skin cancer) up to and including the interval in which the
cases were diagnosed. Controls were matched to cases
on year of birth, menopausal status, postmenopausal
hormone use, and time of day, month and fasting status at
blood sampling. Women were defined as postmenopausal
at the time of a bilateral oophorectomy or after having no
menstrual cycle within the past 12 months before blood
sampling. Women who had had a hysterectomy with one
or both ovaries left intact were classified as pre-
menopausal until the age at which 10% of the cohort had
undergone natural menopause (46 years for smokers and
48 years for nonsmokers), and as postmenopausal at the
age at which 90% of the cohort had undergone natural
menopause (54 for smokers and 56 for nonsmokers).
During the intervening years these women were classified
as being of uncertain menopausal status.
For postmenopausal cases not using postmenopausal
hormones within 3 months before blood sampling, we
matched a second control to increase our statistical
power in plasma steroid hormone analyses. The nested
case–control study consisted of 464 incident breast
cancer cases and 624 matched controls. The study
sample for the plasma hormone analysis was comprised of
298 postmenopausal controls not using hormone replace-
ment therapy within 3 months of blood sampling.
The protocol was approved by the Committee on Human
Subjects, Brigham and Womens’ Hospital, Boston, Mass-
achusetts, USA.
Exposure data
Information regarding breast cancer risk factors was
obtained from the 1976 baseline questionnaire, subsequent
biennial questionnaires, and a questionnaire completed at
the time of blood sampling. Menopausal status and use of
postmenopausal hormones was assessed at blood sam-
pling, and was updated until date of diagnosis for cases and
the equivalent date for matched controls. Histopathologic
characteristics such as stage, tumor size, and ER and PR
status were ascertained from medical records when avail-
able, and used in case subgroup analyses.
Genotyping analysis
DNA was extracted from buffy coat fractions using the
Qiagen QIAamp® Blood Kit (Qiagen Incorporated,
Chatsworth, CA, USA). AIB1 genotyping was performed
as follows. PCR amplification of the polymorphic fragment
was generated using the following primers: 5¢-TTCCGA-
CAACAGAGGGTGG-3¢ (forward) and 5¢-AGTCA-
CATTAGGTGGGC-3¢ (reverse). Forty nanograms of
genomic DNA was used per 22 ml reaction with 1.7 ml of
each 10 mmol/l primer, 4 ml of 10 mmol/l dNTPs, 2.2 ml
10 × PCR buffer, 9.0 ml water and 1.50 U Taq polymerase
(Qiagen Incorporated). Amplification conditions were
http://breast-cancer-research.com/content/2/5/3782 min of initial denaturation at 94°C followed by 35 cycles
of 30 s at 94°C, 90 s at 60°C and 30 s at 72°C, followed
by a final extension at 72°C for 8 min. Two fluorescent 5¢-
labeled primers were utilized, allowing two samples per
lane. A 5% Long Ranger/6 mol/l urea gel (Biowhittaker
Molecular Applications, Rockland, ME, USA) was used for
rapid fragment detection using the ABI Prism 377 DNA
Sequencer (Perkin-Elmer, Foster City, CA, USA) at the
Dana Farber Cancer Institute Molecular Biology Core
Facility and the Harvard Center for Cancer Prevention,
Boston, MA, USA. The size of the amplified products was
determined relative to an internal size standard using
Genescan and Genotyper Analysis software (Perkin-
Elmer). Genotyping was performed by laboratory person-
nel who were blinded to case–control status, and blinded
quality control samples were inserted to validate genotype
identification procedures (n = 110); concordance for the
blinded samples was 100%.
Hormone analysis
Steroid hormone fractions of estrone sulfate, estrone and
estradiol were assayed in up to three separate batches.
Estrone sulfate from batches 1 and 2 were assayed in the
laboratory of Dr C Longcope (University of Massachusetts
Medical Center, Worcester, MA, USA). All other analyses
were performed by at the Nichols Institute (San Juan
Capistrano, CA, USA). Methods for plasma hormone
assays and information regarding laboratory precision and
reproducibility have previously been published [6,19].
Within-batch laboratory coefficients of variation were
13.6% or less.
Statistical analysis
A Mantel–Haenszel c2-test across matched case–control
sets was used to evaluate differences in the frequency of
alleles with 26 repeats or fewer. ORs and 95% CIs were
calculated using conditional and unconditional logistic
regression. In addition to the matching variables, we
adjusted for the following breast cancer risk factors: body
mass index (kg/m2) at age 18 years (continuous); weight
gain since age 18 years (<5, 5–19.9, or ³20 kg); age at
menarche (<12, 12, 13, or >13 years); parity/age at first
birth (nulliparous, one to two children/age at first birth
£24 years, one to two children/age at first birth >24 years,
three or more children/age at first birth £24 years, three or
more children/age at first birth >24 years); first-degree
family history of breast cancer (yes/no); history of benign
breast disease (yes/no); and duration of postmenopausal
hormone use (never; in the past for <5 or ³5 years; or
current for <5 years or ³5 years). We also adjusted for
age at menopause (years) in analyses limited to post-
menopausal women.
To be consistent with prior studies [5], indicator variables
for three AIB1 genotypes were created: two alleles with 26
repeats or fewer, one allele with 26 repeats or fewer, and
two alleles with more than 26 repeats (reference group).
We also evaluated breast cancer risk for specific AIB1
genotypes (28/29, 28/28, 26/29, 26/28 and 26/26) rela-
tive to 29/29 homozygotes. Unconditional logistic regres-
sion models, including terms for the matching variables and
other potential confounders, were used to assess the asso-
ciation between AIB1 alleles and breast cancer character-
ized by histologic subtype, stage of disease, and ER and
PR status. To increase statistical power, all controls were
utilized when cases were limited to clinical parameters and
histologic subtypes. We also evaluated whether breast
cancer risk associated with AIB1 genotype differed
between strata of established breast cancer risk factors.
Because of the low prevalence of genotypes with both
alleles with 26 glutamine repeats or fewer, in stratified
analyses carriers of alleles with 26 repeats or fewer were
compared with noncarriers. Multiplicative interactions were
evaluated by including interaction terms between genotype
and risk factor variables in logistic regression models. The
likelihood ratio test was used to assess the statistical sig-
nificance of these interactions.
Mixed regression models for clustered data were used to
evaluate the association between genotype and circulat-
ing hormone levels among postmenopausal controls, con-
trolling for body mass index at blood sampling and the
matching variables [20]. The natural logarithms of the
plasma hormone values were used in the analyses to
reduce the skew of the regression residuals. Information
regarding outlying values and exclusions were previously
reported [7]. We used the Statistical Analysis System for
all analyses [21].
Results
AIB1 genotype and breast cancer risk
The case–control comparisons of established breast
cancer risk factors among the women studied have previ-
ously been published [7], and are generally consistent
with expectation. The mean age of the women was 58.3
(SD 7.1) years, ranging from 43 to 69 years at blood sam-
pling. There were 188 premenopausal and 810 post-
menopausal women, with mean ages of 48.1 (SD 2.8)
years and 61.4 (SD 5.0) years, respectively, at blood sam-
pling. Women in this study were primarily white; Asians,
African-Americans and Hispanics comprised less than 1%
of cases or controls.
The distribution of AIB1 glutamine repeat alleles and AIB1
genotypes for cases and controls are presented in Table
1. In this study we observed alleles of 19, 22, 25, 26, 27,
28, 29, 30, 31 and 34 repeats, and the expected geno-
type frequencies, based on the allele frequencies among
the cases and controls, were similar to the observed distri-
butions. The allele frequencies were nearly identical for
cases and controls; the most prevalent alleles were of 29
(cases 46.4%, controls 47.8%), 28 (cases 40.4%, controls
Breast Cancer Research    Vol 2 No 5 Haiman et al38.9%), and 26 (cases 12.0%, controls 11.9%) repeats.
Average repeat lengths were also the same for cases and
controls (cases 28.2, controls 28.2). Twenty-six-repeat allele
homozygotes and heterozygotes were evenly distributed
among cases and controls (26/26 homozygotes: cases
1.9%, controls 1.6%; 26/X heterozygotes: cases 20.0%;
controls 20.5%). A cutoff point of 26 repeats or fewer was
used to allow comparison with previously published data [5].
Using this cutoff point, allele frequencies were almost identi-
cal for cases and controls (one or more alleles of 26 repeats
or fewer: 12.1% versus 12.2%; P= 0.82).
Women with 26 repeats or fewer were not at increased
risk for breast cancer; compared with noncarriers, the
adjusted OR for carriers of alleles with 26 repeats or
fewer was 1.01 (95% CI 0.75–1.36; Table 2). Compared
with noncarriers, the adjusted ORs for heterozygotes and
homozygotes for alleles with 26 repeats or fewer were
0.99 (95% CI 0.73–1.35) and 1.29 (95% CI 0.52–3.23),
respectively. Results were also similar by menopausal
status and when adjusting for established breast cancer
risk factors. Among premenopausal women, the OR for
women with at least one allele with 26 repeats or fewer
was 0.82 (95% CI 0.37–1.81), and among post-
menopausal women the corresponding OR was 1.09
(95% CI 0.78–1.52). Compared with 29/29 homozy-
gotes, no significant associations were observed for spe-
cific genotypes with alleles of 26 repeats (Table 2).
AIB1 genotype and tumor characteristics
In analyses by histologic subtype, results were similar
when limiting cases to those with invasive disease, or
advanced stage of disease as characterized by number of
involved lymph nodes, tumor size, and type of carcinoma
(ductal versus lobular; Table 3). Results were also similar
after adjustment for established breast cancer risk factors.
A positive association was observed between short repeat
alleles and poorly differentiated tumors, but this was not
statistically significant (OR 1.54, 95% CI 0.90–2.64). We
did not observe evidence that shorter AIB1 alleles were
associated with a hormone-dependent phenotype. In
case–case analyses, alleles with 26 repeats or fewer were
not over-represented among cases that were positive for
the ER or PR (ER-positive versus ER-negative: 24%
[61/250] versus 21% [12/58], two-tailed Fisher’s Exact
Test [FET] P = 0.61; PR-positive versus PR-negative: 24%
[45/187] versus 22% [24/110], two-tailed FET P = 0.78).
AIB1 genotype–breast cancer risk factor interactions
Because the data of Rebbeck et al [5] suggested that
breast cancer risk associated with carrying a germline
BRCA1 mutation may be modified by AIB1 allele status,
we examined the potential interaction between genotype
and a first-degree family history of breast cancer. In case–
case analyses, women with at least one repeat allele of 26
repeats or fewer were nonsignificantly over-represented
among cases with a family history of breast cancer (family
history versus no family history: 23/83 [27.7%] versus
80/381 [21.0%]; two-tailed FET P = 0.19). However, in
the nested case–control study there was no difference in
association between women with one or more repeat
alleles of 26 or fewer repeats with or without a family
history of breast cancer (family history: OR 1.09, 95% CI
0.46–2.58; no family history: OR 0.94, 95% CI
0.68–1.31; test for interaction P = 0.58).
We evaluated other potential interactions between breast
cancer risk factors and AIB1 alleles with 26 repeats or
fewer. We observed no interactions between short repeat
alleles and the following variables (P values represent
tests for interaction): body mass index among post-
menopausal women (P = 0.89), weight gain since age 18
years (P = 0.41), history of benign breast disease
(P = 0.20), age at menarche (P = 0.24), age at first birth
(P = 0.89) and parity (P = 0.18). We also stratified by oral
contraceptive and postmenopausal hormone use status.
The adjusted ORs for women who had ever and never
used oral contraceptives were 0.75 (95% CI 0.48–1.18)
and 1.22 (95% CI 0.79–1.89), respectively (test for inter-
action P = 0.14). No significant interaction was seen
between carriers of alleles with 26 repeats or fewer and
postmenopausal hormone use (test for interaction
P = 0.41). The OR for alleles with 26 repeats or fewer
among postmenopausal women who had never used hor-
mones was 0.87 (95% CI 0.45–1.66). Similar results
were observed among past users (OR 1.18, 95% CI
0.56–2.47) and current users of short duration (<5 years;
OR 1.16, 95% CI 0.44–3.07). A borderline significant
association was observed among current users who used
postmenopausal hormones for 5 or more years (OR 1.98,
95% CI 0.96–4.07).
AIB1 genotype and hormone levels
Geometric least-squared mean plasma levels of estrone
sulfate and estrone were similar among carriers and non-
carriers of AIB1 alleles of 26 repeats or fewer (both differ-
ences £+3.5%, P > 0.50). Mean levels of estradiol were
slightly, but not significantly elevated among carriers of
alleles with 26 repeats or fewer (+11.6%; P = 0.08). In
analyses among cases the absolute differences were
greater for carriers of alleles with 26 repeats or fewer
(estrone sulfate: +18.5%, P = 0.21; estrone: +14.9%,
P = 0.10; estradiol: +25.0%, P = 0.02).
Discussion
In the present population-based nested case–control
study, women with 26 or fewer repeating glutamine
codons (CAG/CAA) within the carboxyl terminus of
AIB1 were not at increased risk for breast cancer. We
did not observe shorter repeat alleles to be positively
associated with breast cancer, as defined by histologic
subtype or stage of disease, or by ER and PR status. We
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also did not observe evidence that risk associated with
AIB1 allele status is modified by established breast
cancer risk factors.
Coregulators of gene transcription modulate transactiva-
tion of hormone-responsive genes through interactions
with transcription factors and steroid hormone receptors
[1]. Members of the SRC family share similar functional
domains, including a glutamine-rich domain within the car-
boxyl-terminus. Shorter CAG repeat lengths in the andro-
gen receptor are associated with increased transcriptional
activation of that receptor [22], and may be a model for
the potential biologic significance of the polymorphic
repeat in AIB1. The biologic function of this glutamine-rich
region is currently unknown, however, and to our knowl-
edge no studies have correlated this AIB1 repeat poly-
morphism with coactivator activity. Ainzick et al [2] first
reported AIB1 gene amplification in 9.5% (10/105) of
primary breast cancer specimens, and AIB1 mRNA over-
expression in 58% of tumors without AIB1 gene amplifica-
tion relative to normal mammary epithelium. AIB1 was also
found to interact with ERa in a ligand-dependent manner,
and transfection of AIB1 increased estrogen-dependent
transcription. Bautista et al [3] also observed AIB1 gene
amplification in 4.8% (56/1157) of breast and 7.4%
(9/122) of ovarian tumors. In that study gene amplification
was correlated with larger ER-positive and PR-positive
tumors. In a relatively large case–control study (cases
n = 581; controls n = 786), Platz et al [23] observed no
association between germline AIB1 glutamine repeat
length and prostate cancer incidence or stage.
To our knowledge, only one study has examined the asso-
ciation between AIB1 repeat alleles and breast cancer
risk. Among a cohort of 366 BRCA1 mutation carriers,
Rebbeck et al [5] observed a significant association
between  AIB1 alleles with 26 repeats or fewer and breast
cancer risk (OR 1.9, 95% CI 1.5–2.9). These results
suggest that AIB1 genotypes may accentuate BRCA1-
associated breast cancer risk through steroid hormone
pathways. We were unable to examine this particular
question because the study population we studied was
not comprised of women with a high likelihood of carrying
a highly penetrant mutation in BRCA1 (ie early-onset
cases with an extensive family history of breast cancer –
only 18 women had more than one first-degree relative
with breast cancer). In the present study the majority of
cases were postmenopausal at diagnosis (approximately
77%) and were diagnosed as having breast cancer at a
later age (mean 62.7 years). However, the relative risk for
shorter allele carriers was actually nonsignificantly
reduced among premenopausal women (ie those more
likely to carry a BRCA1 mutation). In addition, shorter
repeat alleles were not associated with increased risk for
breast cancer among women with a first-degree family
history of breast cancer.
The strengths of the present study are the relatively large
sample size and prospective design. We had high power
(99.5% at the 0.05 significance level) to detect a significant
relative risk of 2.0 among postmenopausal women, but we
had low power (47.1%) to detect the same magnitude of
association among premenopausal women. AIB1 genotype
may be an important predictor of breast cancer risk among
the small proportion of predisposed women with highly pen-
etrant mutations in breast cancer susceptibility genes.
However, the present data do not provide evidence to
support the hypothesis that AIB1 genotype is involved in
the development of postmenopausal breast cancer among
Caucasian women in the general population.
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